Open pipelines for integrated tumor genome profiles reveal differences between pancreatic cancer tumors and cell lines
暂无分享,去创建一个
James Taylor | Jeremy Goecks | Michael R Rossi | J. Goecks | James Taylor | S. Maithel | H. Khoury | M. Rossi | B. El-Rayes | Shishir K Maithel | Bassel F El-Rayes | H Jean Khoury | Jeremy Goecks
[1] S. Salzberg,et al. TopHat-Fusion: an algorithm for discovery of novel fusion transcripts , 2011, Genome Biology.
[2] Matthew R. Pocock,et al. Taverna: a tool for the composition and enactment of bioinformatics workflows , 2004, Bioinform..
[3] M. Cronin,et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. , 2004, The New England journal of medicine.
[4] Anton Nekrutenko,et al. Making whole genome multiple alignments usable for biologists , 2011, Bioinform..
[5] Anton Nekrutenko,et al. NGS analyses by visualization with Trackster , 2012, Nature Biotechnology.
[6] A. Hauschild,et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. , 2011, The New England journal of medicine.
[7] Jacob A. Tennessen,et al. Evolution and Functional Impact of Rare Coding Variation from Deep Sequencing of Human Exomes , 2012, Science.
[8] E. Gamazon,et al. Identification of novel germline polymorphisms governing capecitabine sensitivity , 2012, Cancer.
[9] Joshua F. McMichael,et al. DGIdb - Mining the druggable genome , 2013, Nature Methods.
[10] Anton Nekrutenko,et al. Web-based visual analysis for high-throughput genomics , 2013, BMC Genomics.
[11] Joel Dudley,et al. Matching Cancer Genomes to Established Cell Lines for Personalized Oncology , 2011, Pacific Symposium on Biocomputing.
[12] D. Altshuler,et al. A map of human genome variation from population-scale sequencing , 2010, Nature.
[13] Steven J. M. Jones,et al. Circos: an information aesthetic for comparative genomics. , 2009, Genome research.
[14] Suzanne Schubbert,et al. Hyperactive Ras in developmental disorders and cancer , 2007, Nature Reviews Cancer.
[15] L. Trusolino,et al. Oncogene addiction as a foundational rationale for targeted anti-cancer therapy: promises and perils , 2011, EMBO molecular medicine.
[16] E. Mardis,et al. Comprehensive genomic studies: emerging regulatory, strategic, and quality assurance challenges for biorepositories. , 2012, American journal of clinical pathology.
[17] Anton Nekrutenko,et al. Harnessing cloud computing with Galaxy Cloud , 2011, Nature Biotechnology.
[18] B. Rigas,et al. A novel Ras inhibitor (MDC-1016) reduces human pancreatic tumor growth in mice. , 2013, Neoplasia.
[19] Winnie S. Liang,et al. Genome-Wide Characterization of Pancreatic Adenocarcinoma Patients Using Next Generation Sequencing , 2012, PloS one.
[20] F. Collins,et al. Policy: NIH plans to enhance reproducibility , 2014, Nature.
[21] Sharmeela Kaushal,et al. KRas induces a Src/PEAK1/ErbB2 kinase amplification loop that drives metastatic growth and therapy resistance in pancreatic cancer. , 2012, Cancer research.
[22] Michael B Atkins,et al. Which drug, and when, for patients with BRAF-mutant melanoma? , 2013, The Lancet. Oncology.
[23] Mingming Jia,et al. COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..
[24] Man Tsuey Tse. Anticancer drugs: A new approach for blocking KRAS , 2013, Nature reviews. Drug discovery.
[25] H. Aburatani,et al. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer , 2007, Nature.
[26] Enis Afgan,et al. BioBlend: automating pipeline analyses within Galaxy and CloudMan , 2013, Bioinform..
[27] H. Hakonarson,et al. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data , 2010, Nucleic acids research.
[28] Cole Trapnell,et al. TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions , 2013, Genome Biology.
[29] Christopher A. Miller,et al. VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. , 2012, Genome research.
[30] Ji Luo,et al. Principles of Cancer Therapy: Oncogene and Non-oncogene Addiction , 2009, Cell.
[31] Anton Nekrutenko,et al. Integrating diverse databases into an unified analysis framework: a Galaxy approach , 2011, Database J. Biol. Databases Curation.
[32] A. Joe,et al. Oncogene addiction. , 2008, Cancer research.
[33] Fumio Nomura,et al. Serum anti-myomegalin antibodies in patients with esophageal squamous cell carcinoma. , 2007, International journal of oncology.
[34] M. Stratton. Exploring the Genomes of Cancer Cells: Progress and Promise , 2011, Science.
[35] M. Scaltriti,et al. Biomarkers of drugs targeting HER‐family signalling in cancer , 2014, The Journal of pathology.
[36] Joon-Oh Park,et al. Impact of KRAS Mutations on Clinical Outcomes in Pancreatic Cancer Patients Treated with First-line Gemcitabine-Based Chemotherapy , 2011, Molecular Cancer Therapeutics.
[37] Life Technologies,et al. A map of human genome variation from population-scale sequencing , 2011 .
[38] Nicole M. Baker,et al. Cancer: Drug for an 'undruggable' protein , 2013, Nature.
[39] M. Atkins,et al. Treatment of BRAF‐Mutant Melanoma: The Role of Vemurafenib and Other Therapies , 2013, Clinical pharmacology and therapeutics.
[40] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[41] David R. Kelley,et al. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.
[42] Adam A. Margolin,et al. The Cancer Cell Line Encyclopedia enables predictive modeling of anticancer drug sensitivity , 2012, Nature.
[43] P. Bastiaens,et al. Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling , 2013, Nature.
[44] A. Nekrutenko,et al. Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences , 2010, Genome Biology.
[45] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[46] Lee T. Sam,et al. Personalized Oncology Through Integrative High-Throughput Sequencing: A Pilot Study , 2011, Science Translational Medicine.
[47] J. Mesirov,et al. GenePattern 2.0 , 2006, Nature Genetics.
[48] Syed Mohsin,et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer , 2003, The Lancet.
[49] Joshua M. Stuart,et al. The Cancer Genome Atlas Pan-Cancer analysis project , 2013, Nature Genetics.
[50] Adam A. Margolin,et al. Enabling transparent and collaborative computational analysis of 12 tumor types within The Cancer Genome Atlas , 2013, Nature Genetics.
[51] M. Gill,et al. Development of Strategies for SNP Detection in RNA-Seq Data: Application to Lymphoblastoid Cell Lines and Evaluation Using 1000 Genomes Data , 2013, PloS one.
[52] Richard Durbin,et al. Sequence analysis Fast and accurate short read alignment with Burrows – Wheeler transform , 2009 .